Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Gilead Sciences has completed its acquisition of Tubulis GmbH, a German clinical-stage biotech specializing in next-generation antibody-drug conjugates (ADCs). The deal was finalized for $3.15 billion in upfront cash on a cash-free, debt-free basis, with up to $1.85 billion in additional contingent milestone payments.
Key figures
- Deal Value Usd
- 3150000000
- Milestone payments
- 1850000000
- Total potential value
- 5000000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.